There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on EDAP TMS (NASDAQ:EDAP) and Sarepta Therapeutics (NASDAQ:SRPT) with bullish sentiments.
EDAP TMS (EDAP)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright initiated coverage with a Buy rating on EDAP TMS and a price target of $6.50. The company’s shares closed on Friday at $3.01.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 11.9% and a 44.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for EDAP TMS with a $6.50 average price target.
See today’s analyst top recommended stocks >>
Sarepta Therapeutics (SRPT)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Sarepta Therapeutics, with a price target of $267. The company’s shares closed on Friday at $138.04.
Chattopadhyay commented:
“Our $267 price target is derived from a risk-adjusted (over its entire clinical-stage pipeline) DCF analysis and is based on: beta of 1.80, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.9%, and tax rate of 15% beginning in FY 2024.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 4.1% and a 50.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $197.06 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
